DDInter94 DDInter1676
Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Anakinra {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Anakinra {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Denileukin diftitox
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Anakinra {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Denileukin diftitox
Anakinra may lead to a major life threatening interaction when taken with Upadacitinib
Anakinra may lead to a major life threatening interaction when taken with Etanercept